Summary of curve fit parameters from results of experiments illustrated in Fig. 4
| Drug | pEC50 | EmaxDRUG/Emax 5-HT | Slope factor | n | |||
|---|---|---|---|---|---|---|---|
| IP | AA | IP | AA | IP | AA | ||
| nm | |||||||
| 5-HT | 7.43 ± 0.11 (37) | 7.34 ± 0.10 (46) | 1.0 | 1.0 | 1.20 ± 0.08 | 1.58 ± 0.24 | 9 |
| Bufotenin | 6.50 ± 0.10 (318) | 6.33 ± 0.08 (468) | 0.78 ± 0.04 | 1.08 ± 0.06 | 1.64 ± 0.22 | 0.97 ± 0.1 | 5 |
| (±)-DOI | 6.72 ± 0.11 (192) | 6.8 ± 0.09 (158) | 0.61 ± 0.07 | 0.97 ± 0.08 | 1.26 ± 0.12 | 1.01 ± 0.12 | 5 |
| d-LSD | 7.80 ± 0.19 (16) | 8.11 ± 0.22 (8) | 0.17 ± 0.02 | 0.39 ± 0.06 | 1.01 ± 0.29 | 1.26 ± 0.45 | 9 |
| Quipazine | 5.89 ± 0.02 (1.29 μ m) | 6.06 ± 0.30 (0.87 μ m) | 0.89 ± 0.12 | 0.59 ± 0.07 | 1.34 ± 0.10 | 1.29 ± 0.24 | 5 |
| TFMPP | 6.34 ± 0.05 (457) | 6.48 ± 0.17 (490) | 1.02 ± 0.13 | 0.59 ± 0.07 | 1.36 ± 0.19 | 1.16 ± 0.16 | 5 |